Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023


U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure

More:
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023

Related Posts